Home > > Middle East & Africa And Global Ovarian Cancer Diagnostics Market- Size, Share, Growth Rate, and Forecast
The Middle East & Africa Ovarian Cancer Diagnostics market was valued at $170.0 Million in 2023, and is projected to reach $251.7 Million by 2030 growing at a CAGR of 5.82% from 2024 to 2030. Imaging segment is expected to be the highest contributor to this market, with $58.5 Million in 2023, and is anticipated to reach $79.0 by 2030, registering a CAGR of 4.43%. Blood Test segment is anticipated to reach $89.4 Million by 2030 with the highest CAGR of 7.29%. Imaging and Blood Test segments collectively expected to account for about 66.6% share of the Middle East & Africa Ovarian Cancer Diagnostics market in 2023, with the former constituting around 34.4% share. Blood Test and Biopsy segments are expected to witness significant growth rates at a CAGR of 7.29% and 4.58% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 59.4% in the overall Middle East & Africa Ovarian Cancer Diagnostics market in 2023, and is anticipated to reach 60.6% by 2030. Diagnosis Type Imaging Blood Test Biopsy Other Diagnosis Types Cancer Type Epithelial Tumor Germ Cell Tumor Stromal Cell Tumor Other Cancer Types End-use Hospital Laboratories Cancer Diagnostic Centers Research Institutes Other End Uses BY REGION North America U.s. Canada Europe Germany U.k. France Italy Spain Rest of Europe Asia China Japan South Korea India Singapore Rest of Asia Middle East & Africa Brazil Mexico South Africa Australia Rest of MENA